RWJBarnabas Health, Rutgers open $225M cancer center

Elizabeth Gregerson / beckershospitalreview - On June 22, West Orange, N.J.-based RWJBarnabas Health and New Brunswick, N.J.-based Rutgers Cancer Institute opened the Melchiorre Cancer Center at Cooperman Barnabas Medical Center in Livingston, N.J. The cancer center cost $225 million, according to a …

AI Summary: Results presented at ASCO for daraxonrasib delivered practice‑changing evidence in pancreatic cancer, prompting clinicians to offer the drug off‑trial within weeks. The data generated excitement across conferences and clinical teams, fueling early adoption discussions and raising hopes for a tangible advance against a historically stubborn disease.


ASCO shockwave: Daraxonrasib survival curve draws standing ovation

5 days / oncodaily

10 days / oncodaily

10 days / oncodaily


Competing KRAS strategies: zoldonrasib, HRS‑4642 and blood testing

7 days / oncodaily

9 days / oncodaily

11 days / medicalxpress


Conference context: RAS momentum and expert reflections

7 days / oncodaily

8 days / oncodaily

11 days / oncodaily

12 days / oncodaily

13 days / oncodaily


Rapid off‑trial rollout and early patient access

17 hrs / oncodaily

6 days / oncodaily

12 days / oncodaily

16 days / oncodaily


All Other Stories

3 days / oncodaily

4 days / oncodaily

5 days / oncodaily

6 days / medicalxpress

6 days / oncodaily

6 days / oncodaily

6 days / oncodaily

6 days / oncodaily

8 days / oncodaily

9 days / oncodaily

9 days / esmo

10 days / oncodaily

12 days / oncodaily

12 days / oncodaily

14 days / oncodaily





Related Stories


Daraxonrasib improves survival versus chemotherapy in metastatic pancreatic cancer / 5 wks

FDA grants early access to experimental pancreatic cancer drug / 2 months

Nine‑year CheckMate‑214 follow‑up confirms durable immunotherapy benefit / 7 days

Teclistamab shows survival benefit prompting earlier use discussions / 21 days

CAR-PRISM trial shows BCMA CAR T effective in high-risk smoldering myeloma / 2 months

Long‑term immunotherapy appears safe for alveolar soft part sarcoma / 2 months

Zongertinib emerges as first-line therapy for HER2‑mutant NSCLC / 2 months

StackHealth RSS


You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Product Recall, Oncology, CDC, Autism and look for the RSS link.





NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.